Efficacy and safety of Ethacizine in patients with paroxysmal atrial fibrillation: analysis of remote electrocardiographic monitoring results

Aim. To evaluate the efficacy and safety of Ethacizine in patients with paroxysmal atrial fibrillation based on remote electrocardiographic monitoring data.

Material and methods. A total of 400 patients were included in this pilot, non-randomized prospective study. They received Ethacizine at a dose of 50 mg 2-3 times daily for 5 weeks to control sinus rhythm. Heart rate, electrocardiographic parame­ters, and the incidence of cardiac arrhythmias were monitored during therapy.

Results. Among patients with available data for each week of the study (n=141), a reduction in the incidence of cardiac arrhythmias was observed with Ethacizine treatment, reaching statistical significance at week 5 of therapy compared with weeks 1, 2, and 3 (p=0,027, p=0,022, and p=0,032, respectively). A favorable safety profile was also noted, based on the absence of significant electrocardiographic deviations and the absence of an increase in the incidence of cardiac arrhythmias after 5-week therapy compared with baseline data.

Conclusion. This study demonstrated a reduction in the incidence of cardiac arrhythmias and the safety of Ethacizine in patients with paroxysmal atrial fibrillation using remote electrocardiographic monitoring.

1. Golukhova EZ, Golitsyn SP, Mikhailov EN, et al. 2025 Clinical practice guidelines for Atrial fibrillation and flutter. Russian Journal of Cardiology. 2025;30(11):6668. (In Russ.) doi:10.15829/1560-4071-2025-6668. EDN: MGXGON.

2. Golitsyn SP, Panchenko EP, Mironov NYu, et al. Eurasian clinical guidelines for the dia­gnosis and treatment of atrial fibrillation in adult patients (2025). Eurasian heart journal. 2025;(3):6-77. (In Russ.) doi:10.38109/2225-1685-2025-3-6-77.

3. Kanorskiy SG, Galenko-Yaroshevsky PA, Alekseenko SN, Golitsyn SP. Atrial fibrillation: Yesterday, today, and tomorrow. Kuban Scientific Medical Bulletin. 2025;32(3):107-20. (In Russ.) doi:10.25207/1608-6228-2025-32-3-107-120.

4. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-16. doi:10.1056/NEJMoa2019422.

5. Becher N, Metzner A, Toennis T, et al. Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur Heart J. 2024;45(31):2824-38. doi:10.1093/eurheartj/ehae373.

6. Zafeiropoulos S, Doundoulakis I, Bekiaridou A, et al. Rhythm vs rate control strategy for atrial fibrillation: a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol. 2024;10(7 Pt 1):1395-405. doi:10.1016/j.jacep.2024.03.006.

7. Sokolov SF, Bomonina EV. Comparative efficacy and safety of allapinine, ethacyzin and amiodarone: choice of optimal antiarrhythmic therapy for rhythm control in case of paroxysmal atrial fibrillation. Kardiologiya: Novosti, mneniya, obuchenie. 2015;(3):65-75. (In Russ.)

8. Tokbulatova MO, Mukanova DA, Keremhanuly N. Optimizaciya lecheniya recidiviruyushchih form fibrillyacii predserdij. Cardiovascular Therapy and Prevention. 2014;13(S2):113. (In Russ.) EDN: SHHNVD.

9. Smirnov VV, Avdeeva MV, Shapovalova AB, et al. Effectiveness and safety of the use of some class 1c drugs in the treatment of heart rhythm disorders in women with climacteric dishormonal cardiomyopathy. Medicine: theory and practice (St. Petersburg). 2023;8(3):15-25. (In Russ.) doi:10.56871/MTP.2023.11.16.002.

10. Fedorova MH, Doshchitsin VL, Chapurnykh AV. Tactics of antiarrhythmic therapy in comorbid elderly and senile patients with paroxysmal and recurrent atrial fibrillation. Rational pharmacotherapy in cardiology. 2018;14(5):670-7. (In Russ.) doi:10.20996/1819-6446-2018-14-5-670-677.

11. Popova (Kishchuk) EP. Comparison of the effects of I class antiarrythmics ethmozine, ethacizin on spectral characteristics of cardiac rhythm variability in rats. Mezhdunarodnyj zhurnal serdca i sosudistyh zabolevanij. 2018;6(17):45-50. (In Russ.) doi:10.24412/2311-1623-2018-17-45-50.

12. Halikova (Hamidzoda) MA, Caregorodcev DA, Beraya MM, Sedov AV. Predictors of class IC antiarrhythmic drugs efficacy in patients with paroxysmal form of atrial fibrillation. Consilium Medicum. 2023;25(10):661-7. (In Russ.) doi:10.26442/20751753.2023.10.202218.

13. Doschitsin VL, Fedorova MH. Treatment of atrial fibrillation in comorbid patients of the senior age. Consilium Medicum. 2018;20(12):47-54. (In Russ.) doi:10.26442/20751753.2018.12.180156.

14. Tsaregorodtsev DA, Sedov AV, Melnyk NV, et al. New opportunities to use noninvasive electrophysiological predictors of sudden cardiac death: predicting efficacy and safety of antiarrhythmic therapy. Russian Journal Of Cardiology And Cardiovascular Surgery. 2015;8(6):114-21. (In Russ.) doi:10.17116/kardio201586114-121.

15. Tsaregorodtsev DA, Okisheva EA, Gracheva EI, et al. The new approach to efficiency and safe evaluation of etacizin in patients without morfological heart pathology. Russian Journal of Cardiology and Cardiovascular Surgery. 2014;7(2):89-96. (In Russ.)

16. Sychov O, Shabilyanova L. Indicators of heart rate variability in patients with paroxysmal and persistent atrial fibrillation: the relationship with the current character, comorbidity and therapy. Cardiology in Belarus. 2016;8(2):263-75. (In Russ.)